City Hall is putting £22m into three projects, two on heart disease, obesity and diabetes. One brings in the south London health network that works in Bromley.

The Mayor of London, Sadiq Khan, is putting £22 million into three projects, two of them aimed at new ways to prevent, detect and treat heart disease, obesity and diabetes. He announced the money on Monday 16 November, the first day of London Life Sciences Week.

City Hall says these cardiometabolic diseases are a leading cause of death and of health inequality in London, and hit Londoners on lower incomes hardest. It says better control of high blood pressure alone could prevent more than 1,200 heart attacks, 1,800 strokes and almost 1,000 deaths in the capital, saving the NHS around £46 million and social care services £12 million.

Overview

  • What: £22m from London’s share of the Local Innovation Partnerships Fund, a UK Research and Innovation (UKRI) programme of up to £500m for innovation clusters across the UK.
  • Where it goes: £5m to a heart disease venture builder run by the BioInnovation Institute and King’s College London; £5m to PHIX London, a health technology testing project led by UCLPartners; £12m to the London Quantum Cluster.
  • Match funding: more than £98m, including pledges, taking the combined investment identified to over £120m.
  • What is left: London’s total allocation is £30m; the rest will be handed out later.

One of the delivery partners on the PHIX London heart project is the Health Innovation Network South London, the NHS innovation body for south London. It already works in this borough: its 2025-26 impact report says AI wound scanning it supported has cut healing times for housebound patients in Bromley, and it is running a Healthy Hearts project with the South East London Integrated Care Board, which covers Bromley, to speed up treatment of high blood pressure, cholesterol, atrial fibrillation and kidney disease in GP surgeries (Health Innovation Network South London).

That project starts from a weak position. The same report says data from the national CVDPREVENT audit shows south east London is below the England average on indicators for the main cardiovascular risk conditions, including high blood pressure. Healthy Hearts is being piloted at six GP sites, one in each south east London borough, with first results expected by late 2026.

Bromley is not among the boroughs named as partners in the new funding: those are Hammersmith & Fulham, Camden and Islington, on the quantum project. The money itself goes to the research and innovation districts in central and west London, not to borough services.

What the three projects do

Heart disease venture builder, £5m. The BioInnovation Institute and King’s College London will help turn cardiometabolic research into new businesses developing treatments and medical technology that could detect heart disease earlier and prevent serious complications.

PHIX London, £5m. Led by UCLPartners, it will work with NHS and private healthcare providers in the Harley Street Health District so that businesses can test and scale new health technology, including better ways to detect and monitor high blood pressure and irregular heart rhythms, and bring them into wider use. Its other delivery partners are the Harley Street Health District, AlbionVC and London’s health innovation networks (Imperial College Health Partners, the Health Innovation Network South London and UCLPartners).

London Quantum Cluster, £12m. A quantum technology group led by UCL, Imperial College London and King’s College London, based in the Knowledge Quarter around King’s Cross, Bloomsbury and Euston and across WestTech London in west London. City Hall says it will help fast-growing companies test technology, raise investment and use quantum technology in healthcare, transport, finance, energy and defence. Industry partners include IBM, Nvidia, Amazon and Canary Wharf Group.

The projects were picked by London’s Frontier Innovation Board after an open call run by the Greater London Authority, and assessed by an independent expert panel convened by UKRI. UKRI and the GLA will manage the grants.

What they said

In his speech at the launch, the Mayor was expected to say: “London is one of the most exciting life sciences hubs in the world, thanks to our unique combination of world-leading research, clinical innovation and commercial expertise. But now we want to go even further and make London not just the European capital for life sciences, but the world capital.”

He was also expected to say: “Our commitment has also helped unlock nearly £100 million in match funding, sparking a chain reaction of investment that will create jobs, drive growth and fast-track innovation.”

Professor Kevin Fenton, Regional Director of Public Health for NHS London and OHID London, said: “Preventing cardiovascular disease (CVD) is one of London’s biggest public health priorities, and achieving our ambitions will require new ideas, stronger partnerships and faster adoption of proven innovations. These two complementary proposals connect research, venture development, clinical testing and NHS implementation, helping promising discoveries reach the people and communities who need them most. Together, they could strengthen London’s Million Hearts and Minds prevention programme, reduce inequalities and position London as a global leader in cardiovascular innovation.”

Professor Sir Ian Chapman, chief executive of UKRI, said the fund’s investments would “add to that mix”, adding: “UKRI is supporting local partnerships right across the UK to build on their distinctive strengths, translating innovation into impact that advances knowledge, improves lives and drives growth.”

Laura Citron, chief executive of London & Partners and chair of the Frontier Innovation Board, said: “London is full of brilliant ideas and talented people. Helping those ideas succeed here has the potential to make life better for Londoners, but it also means creating exciting careers, especially in new industries like quantum.”

London’s life sciences in numbers

City Hall says London has more than 2,700 life sciences companies and around 40,000 jobs in the sector. Dealroom figures analysed by London & Partners show London’s life sciences firms have raised $3.2 billion in venture capital so far in 2026, 35% more than in the whole of 2025 ($2.4 billion), and more than three times as much as Paris ($933 million).

London Life Sciences Week, run by the UK BioIndustry Association, MedCity and London & Partners, brings more than 5,000 investors, researchers and industry leaders to the capital this week.

Source: Mayor of London press office.